Free Newsletter
Lilly's ED drug gets daily dose
Eli Lilly's tadalafil was the little blue pill's lesser sibling at first, but it's gained momentum, especially outside the U.S. With a low-dose pill approved yesterday by the FDA, is may just pull ahead domestically, too.
Taken daily, the low-dose version allows men to attempt sexual activity anytime. Previously, men had to take tadalafil ahead of time; it remained effective for 36 hours. Other treatments work for about four hours.
Lilly hopes that this new, more convenient dosing helps sales continue to grow: For the first nine months of 2007, the drug brought in $798 million, and the company expects it to top $1 billion for the full year. The nine-months results are 30 percent higher than same-period-last-year sales.
- here's Lilly's release
- read the article from the Indianapolis Star
Related Article:
Lilly reports significant gains in tadalafil study. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: